Original Reports

Analysis of the tracked dataset, published in full with the method stated.

Direct answer

Reports are our own analysis of the dataset rather than coverage of somebody else's announcement.

Each states its method, links the underlying file, and says what it could not establish.

For context: across 32 tracked tirzepatide telehealth programmes, 17 publish a price we could capture, and the cheapest verified all-in cost is $215 a month at a 10 mg maintenance dose — about $2,580 for a first year. Compounded preparations are not FDA-approved. Prices captured 2026-08-05.

First-year all-in cost

NexLife$2,580Join Fridays$2,988Yucca Health$3,096IVIM Health$3,219ShedRx$3,318Mochi Health$3,336SkinnyRx$3,588Amble Health$3,600Lavender Sky Health$3,971TrimRx$4,188Found$4,776MEDVi$4,788
Two months of titration plus ten at a 10 mg maintenance dose, membership included. Captured 2026-08-05.

The reports

Primary sources

Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.

  1. FDA — Human Drug Compounding
  2. FDA — Warning Letters
  3. NABP — State Boards of Pharmacy directory
  4. FTC — Health Products Compliance Guidance

Why publish analysis at all

Because the most useful findings in this category are about the information rather than the medicine. How often published prices are wrong, in which direction, and what structural incentive produces the error are questions no individual programme will answer about itself, and they change how a reader should treat every other comparison they encounter.

The method, in one paragraph

We hold one dataset covering 32 programmes: all-in monthly cost at six dose tiers, first-year totals, fee structure, commitment terms, care model, pharmacy disclosure, evidence status and source, each with a capture date. Reports compute over that file and nothing else. Where a finding depends on a figure we could not verify, the report says so rather than rounding the uncertainty away.

What a report will never contain

An estimated price, an invented rating, or a conclusion that cannot be reproduced from the published file. If a chart here cannot be rebuilt from the dataset, that is a defect and we want to hear about it.

Reuse

Cite freely with attribution and carry the capture date shown on the figure. Journalists and analysts can take the underlying file directly from the data page rather than transcribing from a table.